Leadership Appointed in Suboxone MDL
The initial status conference for the Suboxone tooth decay lawsuit was held on March 7, 2024, before Judge Philip Calabrese in the United States District Court for the Southern District of Ohio. Matthew Dolman and Stanley Gipe from Dolman Law Group attended, with Stanley Gipe appointed to the Plaintiff’s Steering Committee.
FDA Warning Label Update
The FDA revised the warning label for Suboxone sublingual film in late June 2022, highlighting serious dental injuries reported by individuals using sublingual medications containing buprenorphine. Reported injuries included severe dental decay, oral infections, tooth loss, cavities, and other dental issues.
Anticipated Lawsuit Influx
A surge of Suboxone tooth decay lawsuits is expected to be filed by June 1, 2024, following the FDA’s warning label update. However, some states have a 2-year statute of limitations on product liability/failure to warn claims, leading many law firms to be selective in representing Suboxone tooth decay clients in those states.
Future of the MDL
Despite limitations in certain states, it is anticipated that the MDL will experience a significant increase in lawsuits over the next eighty days. As of June 2024, the FDA had received reports of 305 cases of dental problems from individuals using sublingual buprenorphine, with many experiencing tooth decay within an average of two years following long-term exposure to sublingual Suboxone film.
